GDUFA III Drug Master File (DMF) Review Enhancements
The FDA’s GDUFA III reauthorization adds a mechanism for early review of Type II API drug master files up to six months before an ANDA or prior‑approval supplement is filed. A draft guidance explains how DMF holders can request a “DMF prior assessment” and the triggers that prompt FDA to begin the review. It also outlines data‑submission expectations and coordination steps among ANDA applicants, DMF owners, and the agency. The goal is to streamline communication and cut approval delays for generic drugs.
KUKA FLEX CBD May Be Harmful Due to Hidden Drug Ingredient
The FDA issued a safety alert after laboratory testing revealed that KUKA FLEX CBD, sold online and in some stores for joint pain, contains the prescription NSAID diclofenac, which is not disclosed on the label. Diclofenac can trigger cardiovascular events, serious gastrointestinal...
Curcuflex May Be Harmful Due to Hidden Drug Ingredients
The U.S. Food and Drug Administration has warned consumers to avoid Curcuflex, a joint‑pain product sold online and in some stores, after laboratory testing revealed it contains the prescription drugs dexamethasone and diclofenac, neither of which appear on the label....
RM Joe May Be Harmful Due to Hidden Drug Ingredients
The FDA has issued a safety alert that the joint‑pain product RM Joe, sold online and in some stores, contains undeclared dexamethasone phosphate and diclofenac. Laboratory testing confirmed the hidden prescription‑drug ingredients, which can trigger severe steroid‑related and NSAID‑related side effects....
Yeicob Ácido Hialurónico May Be Harmful Due to Hidden Drug Ingredients
The FDA has warned that Yeicob Ácido Hialurónico, marketed for joint pain, contains undeclared dexamethasone phosphate and diclofenac. Laboratory testing confirmed these prescription‑grade drugs are hidden in the supplement’s label. The agency advises consumers to stop using the product and...
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
The BioPharm Brief highlights three pivotal biopharma trends: early‑stage process design flaws can cripple cell and gene therapy scale‑up, leronlimab demonstrates early clinical and biomarker activity in metastatic colorectal cancer, and Amneal Pharmaceuticals’ acquisition of Kashiv BioSciences creates a vertically...
STAT+: At AACR, Talk of Chinese Biotech, Oncology’s Comms Issue, and More
Revolution Medicines highlighted two key updates at the AACR meeting: promising frontline pancreatic cancer data for its RAS inhibitor daraxonrasib and the introduction of a novel compound, RM-055. RM-055 is described as a catalytic inhibitor that can strip a phosphate...
FDA Warns Device Manufacturers of Nitrosamine Impurities that Could Cause Cancer
The FDA’s Center for Devices and Radiological Health has issued a warning to manufacturers of drug‑device combination products about the presence of nitrosamine impurities, specifically 1‑methyl‑4‑nitrosopiperazine, detected in rifampin‑impregnated devices. The agency highlighted that catheters, cardiac‑implant envelopes, and other devices...
CVS Claims It’s on the Verge of Losing All Its Pharmacies in Tennessee
CVS Health warns that the Tennessee Fair Rx Act, now passed by the state Senate, would force it to shut down all more than 100 retail pharmacies and 25 MinuteClinic locations in the state. The bill bars companies that own...
An Experimental New Drug for Stiff Person Syndrome Restores Mobility
Researchers at Kyverna Therapeutics reported that a single infusion of their experimental CAR‑T cell therapy, miv‑cel, dramatically improved mobility in patients with stiff person syndrome (SPS). In a Phase II trial of 26 participants, walking speed increased and eight of twelve...
BioMérieux Unveils BIOFIRE SPOTFIRE Molecular Testing Solution for Biopharma
bioMérieux has launched BIOFIRE SPOTFIRE, a molecular testing system aimed at biopharma quality control. The instrument delivers mycoplasma results in less than an hour, leveraging automated workflows, touchscreen operation, and barcode scanning. Designed to be compact and stackable, it integrates with...
Ocrelizumab in PPMS. Complementing Regulatory History with a Decade of Clinical Evidence
Roche’s ocrelizumab (Ocrevus) is the only FDA‑approved disease‑modifying therapy for primary progressive multiple sclerosis (PPMS). Since its 2017 approval based on the ORATORIO trial, a decade of data—including the 2025 O’HAND study and ten‑year extension analyses—has confirmed robust efficacy across...
Why Early Process Design Is Key to Cell and Gene Therapy Success
At INTERPHEX 2026, Charles River’s Dr. Alan Smith warned that cell and gene therapy developers often prioritize rapid first‑in‑human studies at the expense of scalable manufacturing. He highlighted recurring gaps where insufficient early‑stage process design forces costly redesigns during later trials or...
10x Science: The Founders Who Built the Field Are Now Building the Platform
10x Science is launching an AI‑driven platform that automates molecular characterization of biologic drugs, a step traditionally performed manually by PhD scientists using outdated software. The company’s founders—two Stanford‑trained researchers with Nobel‑linked publications and a veteran YC entrepreneur—bring deep scientific...
FDA Clinical Trials Training Modules
The FDA’s Center for Drug Evaluation and Research has released new clinical‑trial training modules that capture the agency’s latest regulatory intelligence, emerging guidance, and real‑world compliance experience. The curriculum serves as a global benchmark, helping organizations demonstrate regulatory excellence and...
Relaxing the Rules: How Claim Type Supported Patent Validity for Teva Pharmaceuticals’ “Headache Patents”
The Federal Circuit reversed a lower‑court ruling that invalidated Teva Pharmaceuticals’ “headache patents,” holding that the method‑of‑treatment claims satisfied written description and enablement requirements. The court emphasized that the claims were directed to using humanized mouse antibodies, not the antibodies...
Scientists Found a Chemical That Could Help Regrow Your Hair. It Might Be In Your Pantry.
Researchers from China and Australia have created a dissolving microneedle patch that combines minoxidil with stevioside, a natural sweetener from the Stevia plant, to improve hair‑loss treatment. The stevioside acts as a solubilizing agent, enhancing minoxidil's water solubility and skin...
Leronlimab Shows Early Clinical and Biomarker Activity in Metastatic Colorectal Cancer at AACR 2026
CytoDyn presented early Phase 2 results showing that leronlimab combined with TAS‑102 and bevacizumab markedly reduced circulating tumor DNA in metastatic colorectal cancer patients. CCR5 expression was confirmed in all prescreened tumors, and median ctDNA fell about 70% by week two...
We Need More Radioactive Drugs. Can We Make Them From Nuclear Waste?
A new wave of radiopharmaceutical cancer treatments is driving unprecedented demand for radioisotopes, prompting companies to extract them from legacy nuclear waste. Researchers at the UK National Nuclear Laboratory are refining radioactive lead from stored waste, while firms like Belgium’s...
FDA PreCheck Pilot Program Structure
The FDA PreCheck Pilot Program is a two‑phase initiative aimed at speeding the launch of new U.S. pharmaceutical manufacturing sites. Phase 1 delivers early engagement through Pre‑Operational Reviews and the creation of a Type V Drug Master File that documents facility design,...
Nipocalimab Demonstrates Sustained Disease Control Over Two Years in Generalized Myasthenia Gravis
Johnson & Johnson announced that nipocalimab (Imaavy) sustained disease control in generalized myasthenia gravis for over two years, extending efficacy beyond the initial 24‑week trial to 120 weeks. Patients showed mean reductions of 6.47 points on the MG‑ADL and 5.97...
First Non-INSTI, Tenofovir-Free Regimen DOR/ISL Gains FDA Approval for HIV
The FDA has approved Merck’s Idvysno, a once‑daily, single‑tablet combination of doravirine and islatravir, marking the first non‑INSTI, tenofovir‑free two‑drug regimen for adults with virologically suppressed HIV‑1. Phase 3 trials demonstrated non‑inferior viral suppression compared with standard three‑drug regimens, with only...
Moderna, After Losing US Funding, Rebounds to Start mRNA Bird Flu Vaccine Trial
Moderna has launched a Phase 3 trial of its mRNA‑1018 bird‑flu vaccine, enrolling about 4,000 healthy adults in the United States and the United Kingdom. The study follows the loss of a $766 million U.S. government contract, which had funded earlier development...
FDA Expands Teplizumab-Mzwv Approval to Young Children With Stage 2 T1D
The FDA granted supplemental approval for Sanofi’s teplizumab‑mzwv (Tzield) to treat children as young as one year with stage 2 type 1 diabetes, expanding the prior 8‑year‑and‑up indication. The decision follows interim data from the PETITE‑T1D phase 4 trial, where 23 children received...
Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?
In June 2025 the FDA approved MSD’s Keytruda (pembrolizumab) for resectable locally advanced head‑and‑neck squamous cell carcinoma (LA HNSCC) with PD‑L1 CPS ≥ 1, based on the KEYNOTE‑689 trial. A separate adjuvant nivolumab study (NIVOPOSTOP) showed promising results, though regulatory filing is...
STAT+: Gene Therapy Trial for Deafness Adds Evidence to Drug’s Efficacy
Researchers have reported that a gene‑therapy injection dramatically improved hearing in a Chinese clinical trial, with 90% of participants noting significant gains. The study, published in Nature, includes both children and adults, such as a 32‑year‑old who regained functional hearing....
The META-AF Trial
Researchers launched the META‑AF trial to evaluate metformin as an adjunct to catheter ablation in atrial fibrillation patients. The study randomizes roughly 500 participants to receive metformin or placebo beginning two weeks before ablation, with follow‑up through 12 months. Primary...
Restrictions on Obesity Drug Coverage Force Patients to Pivot
Insurance giants CVS Caremark and other carriers are pulling popular GLP‑1 obesity drugs such as Zepbound and Wegovy from many formularies, leaving millions of patients without coverage. GoodRx data shows 12 million people lost Zepbound and another 12 million lost Wegovy between...
AI Is Spitting Out More Potential Drugs than Ever. This Start-Up Wants to Figure Out Which Ones Matter.
10x Science, a biotech AI startup founded by former Stanford researchers, announced a $4.8 million seed round led by Initialized Capital. The company’s platform combines deterministic chemistry algorithms with AI agents to automatically interpret mass‑spectrometry data, turning raw spectra into actionable...
Immunotherapy Drug Helps Bladder Cancer Patients Avoid Major Organ Removal
A phase‑2 trial led by NYU Langone Health found that adding pembrolizumab (Keytruda) to standard chemotherapy, radiation, and surgery allowed 60% of patients with muscle‑invasive bladder cancer to avoid cystectomy for up to two years. The study, the largest of...
Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance
The Centers for Medicare & Medicaid Services (CMS) has indefinitely postponed its BALANCE financing model, a pilot intended to expand Medicare coverage for GLP‑1 obesity drugs. The delay triggered a roughly 2% drop in Eli Lilly’s share price and a 4%...
Expanding the Toolkit: Non-Statin Therapies, Broader Populations, and Closing the Treatment Gap
The 2026 ACC/AHA guideline now gives strong, Class I recommendations for non‑statin therapies—bempedoic acid, PCSK9 antibodies, ezetimibe and inclisiran—for patients who cannot tolerate statins. It endorses combination regimens, such as a moderate‑intensity statin plus ezetimibe, which the RACING trial showed matches...
INBRAIN Neuroelectronics Completes Patient Recruitment for First-in-Human Study Evaluating Its Graphene Cortical Interface
INBRAIN Neuroelectronics announced that patient recruitment is complete for its first‑in‑human trial of a graphene‑based cortical interface. Ten patients were enrolled, and eight underwent surgery without any peri‑operative device failures, yielding complete datasets. The study, run with the University of...
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Ray Therapeutics announced a $125 million Series B round, led by Janus Henderson Investors with participation from Merck’s venture arm, MRL Ventures and Novo Holdings. The capital will fund late‑stage clinical work and commercial preparation for RTX‑015, its lead gene‑therapy candidate for...
Immunotherapy Offers Hope in Avoiding Bladder Removal for Cancer Patients
A new immunotherapy regimen combining checkpoint inhibitor pembrolizumab with standard chemoradiation has demonstrated a high rate of bladder preservation in patients with muscle‑invasive bladder cancer. In a multinational Phase III trial of 560 participants, 68% of patients avoided cystectomy at...
Amid US Ordeal, Moderna Wins EU Approval for Flu/COVID-19 Combo Shot
Moderna received European Commission approval for its mCOMBRIAX vaccine, a combined flu and COVID‑19 shot targeting adults 50 and older across all 27 EU members plus Iceland, Liechtenstein and Norway. The combo pairs Moderna’s next‑generation COVID vaccine mNEXSPIKE with the...
An ‘AI Scientist’ Can Tackle Drug R&D. What Does that Mean for Pharma?
AI agents are moving from analytical tools to autonomous coworkers in pharma, with Owkin’s K Pro platform acting as an “AI scientist” that can answer complex research questions in hours rather than weeks. The system pulls together literature, gene‑expression data, and...
New Data Build Case for Roche's Oral BTK Drug for MS
Roche reported that its oral BTK inhibitor fenebrutinib dramatically reduced relapse rates and MRI lesions in two phase 3 FENhance trials for relapsing multiple sclerosis, outperforming Sanofi's Aubagio. The drug cut annualised relapse rates by 51.1% and 58.5% and lowered inflammation...
Regeneron Reports P-III (NIMBLE) Trial Data on Cemdisiran for Generalized Myasthenia Gravis (gMG)
Regeneron presented Phase III (NIMBLE) data showing that subcutaneous cemdisiran 600 mg every 12 weeks significantly improved symptoms in adults with generalized myasthenia gravis (gMG) and anti‑AChR antibodies. Over 24 weeks, the cemdisiran arm reduced MG‑ADL scores by 4.5 points versus 2.2...
Merck Steps up as 'Meaningful Competitor' To Gilead with HIV Pill Approval
Merck received FDA approval for Idvynso, a once‑daily, single‑pill regimen for virologically suppressed HIV‑1 adults, slated for U.S. launch on May 11, 2026. The drug demonstrated non‑inferior viral suppression versus continued Biktarvy use in two pivotal trials. Analysts see Idvynso...
FDA Approves MSD’s Once-Daily HIV Combo Idvynso
Merck’s Idvynso (doravirine/islatravir) received FDA approval, marking the first tenofovir‑free, non‑INSTI two‑drug regimen for HIV. The decision follows Phase III trials that demonstrated non‑inferior viral suppression compared with Gilead’s three‑drug standard Biktarvy. Idvynso targets virologically suppressed patients without prior treatment failure...
Ipsen’s Ojemda (Tovorafenib) Receives Conditional Approval for R/R BRAF-Altered Pediatric Low-Grade Glioma (pLGG) in the EU
Ipsen’s oral kinase inhibitor Ojemda (tovorafenib) received conditional approval from the European Commission for treating pediatric low‑grade glioma (pLGG) with BRAF fusions, rearrangements or V600 mutations. The indication applies to patients six months or older who have progressed after at...
Rapid Blood Infection Test Fails to Improve Survival
A large, open‑label randomized trial of 899 patients with gram‑negative bacteremia compared rapid antimicrobial susceptibility testing directly from positive blood cultures to standard sub‑culture testing. The rapid approach delivered susceptibility results in about 7.5 hours versus 44 hours for the conventional method,...
New Nanomedicine Approach Boosts Chemotherapy And Immune Activity In Pancreatic Cancer
A preclinical mouse study published in Advanced Science demonstrates that photoactivatable multi‑inhibitor liposomes (PMILs) can deliver irinotecan directly to pancreatic ductal adenocarcinoma (PDAC) tumors when activated by light. The regimen combines minocycline‑mediated DNA‑repair inhibition, photodynamic priming, and localized chemotherapy, boosting...
BioAegis and Prenosis Partner for Inflammatory Disease Therapies
BioAegis Therapeutics has teamed up with AI‑focused startup Prenosis to accelerate precision‑medicine approaches for inflammatory diseases. The partnership will analyze biospecimens from BioAegis’s Phase II BTI‑203 trial of recombinant human plasma gelsolin in 600 ARDS patients across Europe, Canada and the...
Medicare Obesity Drug Pilot Extended After Insurer Pushback
The Trump administration has pushed back the start of the Medicare GLP‑1 Bridge pilot by a year after insurers fell short of the 80% enrollment target. The federal government will continue to cover drugs such as Novo Nordisk’s Wegovy, Eli Lilly’s...
Senators Grill RFK Jr. On Vaccines, Drug Prices and More at Hearing
Health Secretary Robert F. Kennedy Jr. faced intense questioning from Senate Finance and HELP committees, with Democrats probing his vaccine policies, promotional video costs, and the TrumpRx drug‑discount platform. Republicans highlighted his rural health initiatives and progress on food‑dye reductions,...
Amazon Just Put the Biggest Trade of the Decade on the Wrong Side—And Big Pharma Is Paying for It
Amazon has launched a direct‑to‑patient pricing model for GLP‑1 drugs, offering cash‑pay rates of $25 per month for insured patients, $149 for oral pills and $299 for injectables such as Wegovy and Zepbound. The pricing, combined with same‑day delivery to...
Genentech Reports the P-III (METEOROID) Trial Data on Enspryng (Satralizumab) to Treat MOGAD
Genentech presented Phase III METEOROID trial results for Enspryng (satralizumab) in patients aged 12 and older with myelin oligodendrocyte glycoprotein antibody‑associated disease (MOGAD). The study met its primary endpoint, showing 87% of participants remained relapse‑free at 48 weeks versus 67%...
PARP Inhibitors: A Proven Class Facing Limits
PARP inhibitors have reshaped treatment for BRCA‑mutated cancers by exploiting synthetic lethality, but their expansion beyond this niche faces hurdles. While ovarian, breast, pancreatic, and prostate indications now include PARP‑based maintenance or combination regimens, inconsistent benefits in HRD‑positive and broader...